Antitumor Activity of a Duocarmycin Analogue Rationalised to Be Metabolically Activated by Cytochrome P450 1a1 in Human Transitional Cell Carcinoma of the Bladder

ANTITUMOR ACTIVITY OF A DUOCARMYCIN ANALOGUE RATIONALISED TO BE METABOLICALLY ACTIVATED BY CYTOCHROME P450 1A1 IN HUMAN TRANSITIONAL CELL CARCINOMA OF THE BLADDER. Mark Sutherland, Jason H. Gill, Paul M. Loadman, Jonathan P. Laye, Helen M. Sheldrake, Nicola A. Illingworth, Mohammed N. Alandas, Patricia A. Cooper, Mark Searcey, Klaus Pors, Steve D. Shnyder, Laurence H. Patterson Institute of Cancer Therapeutics, University of Bradford, Bradford, BD7 1DP. UK School of Medicine, Pharmacy and Health, Durham University, Stockton-on-Tees, UK School of Pharmacy, University of East Anglia, Norwich, UK † Current Address: Leeds Institute of Molecular Medicine, University of Leeds, UK § Current Address: Clinical Trials Service Unit (CTSU), University of Oxford, UK *Requests for reprints: Laurence Patterson, Institute of Cancer Therapeutics, University of Bradford, Tumbling Hill Street, Bradford BD7 1DP, UK. Phone: +44 (0)1274-233226; Fax: +44 (0)1274-233234. Email: [email protected]